MX428952B - Métodos de uso y composiciones que incluyen un análogo de incretina - Google Patents

Métodos de uso y composiciones que incluyen un análogo de incretina

Info

Publication number
MX428952B
MX428952B MX2024000213A MX2024000213A MX428952B MX 428952 B MX428952 B MX 428952B MX 2024000213 A MX2024000213 A MX 2024000213A MX 2024000213 A MX2024000213 A MX 2024000213A MX 428952 B MX428952 B MX 428952B
Authority
MX
Mexico
Prior art keywords
compositions
methods
glucagon
incretin
doses
Prior art date
Application number
MX2024000213A
Other languages
English (en)
Other versions
MX2024000213A (es
Inventor
Tamer Coskun
Zvonko Milicevic
Shweta Urva
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2024000213A publication Critical patent/MX2024000213A/es
Publication of MX428952B publication Critical patent/MX428952B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen dosis y regímenes de dosificación para análogos de incretina que comprenden la determinación y administración de dosis de análogos de incretina de acción prolongada adecuados para la dosificación una vez por semana, tal como un agonista triple de receptores de polipéptido insulinotrópico dependiente de glucosa (GIP), péptido similar al glucagón-1 (GLP-1) y glucagón (GCG) (GGG).
MX2024000213A 2021-06-23 2022-06-22 Métodos de uso y composiciones que incluyen un análogo de incretina MX428952B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163213956P 2021-06-23 2021-06-23
PCT/US2022/034437 WO2022271767A1 (en) 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management

Publications (2)

Publication Number Publication Date
MX2024000213A MX2024000213A (es) 2024-04-16
MX428952B true MX428952B (es) 2025-11-13

Family

ID=82608370

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2024000213A MX428952B (es) 2021-06-23 2022-06-22 Métodos de uso y composiciones que incluyen un análogo de incretina
MX2025012714A MX2025012714A (es) 2021-06-23 2024-01-03 Metodos de uso y composiciones que incluyen un analogo de incretina
MX2025012713A MX2025012713A (es) 2021-06-23 2024-01-03 Metodos de uso y composiciones que incluyen un analogo de incretina

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2025012714A MX2025012714A (es) 2021-06-23 2024-01-03 Metodos de uso y composiciones que incluyen un analogo de incretina
MX2025012713A MX2025012713A (es) 2021-06-23 2024-01-03 Metodos de uso y composiciones que incluyen un analogo de incretina

Country Status (11)

Country Link
US (3) US12496329B2 (es)
EP (1) EP4358994A1 (es)
JP (1) JP2024524180A (es)
KR (1) KR20240024936A (es)
CN (1) CN117915939A (es)
AU (2) AU2022298662B2 (es)
BR (1) BR112023027321A2 (es)
CA (1) CA3223313A1 (es)
IL (1) IL309604B1 (es)
MX (3) MX428952B (es)
WO (1) WO2022271767A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021034815A1 (en) * 2019-08-19 2021-02-25 Eli Lilly And Company Methods of making incretin analogs
CA3208873A1 (en) * 2021-02-17 2022-08-25 Mathijs Christiaan Michael BUNCK Gip/glp1 dual agonist therapeutic methods
TW202611066A (zh) * 2024-08-16 2026-03-16 大陸商江蘇恆瑞醫藥股份有限公司 Glp-1類似物的醫藥用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2708252T3 (en) 2010-03-01 2015-11-02 Lilly Co Eli Automatic injection device with delay mechanism including double acting biasing element
MA50798A (fr) 2017-11-21 2020-09-30 Lilly Co Eli Procédés d'utilisation et compositions contenant du dulaglutide
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI810937B (zh) 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
TW202228762A (zh) 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途

Also Published As

Publication number Publication date
JP2024524180A (ja) 2024-07-05
BR112023027321A2 (pt) 2024-03-12
MX2024000213A (es) 2024-04-16
AU2022298662A1 (en) 2024-01-18
AU2025220848A1 (en) 2025-09-11
MX2025012713A (es) 2025-11-03
CA3223313A1 (en) 2022-12-29
KR20240024936A (ko) 2024-02-26
US20240325498A1 (en) 2024-10-03
US20260091087A1 (en) 2026-04-02
AU2022298662B2 (en) 2025-06-05
WO2022271767A1 (en) 2022-12-29
MX2025012714A (es) 2025-11-03
US12496329B2 (en) 2025-12-16
US20260091088A1 (en) 2026-04-02
IL309604B1 (en) 2026-06-01
CN117915939A (zh) 2024-04-19
EP4358994A1 (en) 2024-05-01
IL309604A (en) 2024-02-01